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Fatty acid amide hydrolase (FAAH) inhibitors are addressed for promising anxiolytics, but human
studies on genetically reduced FAAH activity, stress and affective phenotypes are scarce. We
investigated the effect of a functional polymorphism of FAAH (FAAH C385A or rs324420; low FAAH
activity and high anandamide concentration are associated with the A allele) together with
childhood adversity on the anxious and depressive phenotypes in 858 subjects from the general
population. Phenotypes were measured by the Zung Self-Rating Depression Scale (ZSDS), the
depression and anxiety subscales of the Brief Symptom Inventory (BSI-DEP, BSI-ANX) and the
State-Trait Anxiety scales (STAI-S, STAI-T). Childhood Adversity Questionnaire (CHA) was used to
assess early life traumas. Frequency of the A allele was greater among subjects with high ZSDS
scores compared to the CC genotype. Furthermore, FAAH C385A and the CHA have shown a robust
gene–environment interaction, namely, signiﬁcantly higher anxiety and depression scores were
exhibited by individuals carrying the A allele if they had high CHA scores compared to CC carriers.
These data provided preliminary evidence that genetically reduced FAAH activity and repetitive
stress in the childhood are associated with increased vulnerability for anxiety and depression in
later life. Our results together with earlier experimental data suggest that permanently elevated
anandamide level together with early life stress may cause a lifelong damage on stress responseo.2016.03.003
CNP. All rights reserved.
nt of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary.
com (J. Lazary).
1021Genetically reduced FAAH activityprobably via the downregulation of CB1R during the neurodevelopment in the brain. It may also
point to pharmacogenomic consequences, namely ineffectiveness or adverse effects of FAAH
inhibitors in this subpopulation.
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The pathological role of stress in the development of affective
disorders has been well known for a long time and the
underlying molecular mechanism is intensively investigated.
Biological evidence supports that childhood trauma leads to
marked disturbance of molecular and structural development
in the neuroendocrine regulatory system, such as HPA hyper-
activity, increased immune activation and reduced hippocam-
pal volume which is also detectable in anxious and depressive
disorders (Heim et al., 2008; Frodl and O'Keane, 2013).
Further, in epigenetic studies hypermethylation of the DNA
in the region of glucocorticoid receptor and BDNF gene
promoters have been found in suicide victims who were
exposed to childhood trauma (McGowan et al., 2009; Keller
et al., 2010).These data suggest that early life trauma causes
lifelong changes in the HPA axis, the major regulatory system
for the stress response.
The endocannabinoid (eCB) system has a special role in
buffering stress reaction due to its unique effect on
recovery from stress. The eCB system is composed of
receptors (cannabinoid type 1 receptor, CB1R and cannabi-
noid type 2 receptor, CB2R), endocannabinoids (eCBs, such
as 2-arachidonoylglycerol, 2-AG; anandamide, AEA and
N-acylethanolamine, NEA), transporter, synthetizing, and
catabolic enzymes. The CB1Rs are highly expressed in
corticolimbic regions mediating anxiety, including the med-
ial prefrontal cortex, the hippocampus and the basolateral
amygdala (Mackie, 2005). CB2Rs are presented mainly in the
periphery but are also expressed with less activity in
microglia and some neuronal population of the brain
(Onaivi et al., 2006). The main substrates of the CB1Rs
are the 2-AG and AEA and activated CB1Rs have an inhibit-
ing effect on the release of several neurotransmitters
including GABA and glutamate. The fatty acid amide hydro-
lase (FAAH) enzyme is responsible for the AEA degradation,
thus it indirectly regulates the CB1R signaling via the
modulation of the availability of AEA.
During the initial phase of acute stress the concentration
of AEA is decreased by FAAH hydrolysis in the amygdala and
prefrontal cortex which allow HPA activation and optimal
fast cortisol response (Hill et al., 2009; McLaughlin et al.,
2014). Following this quick stress-response the eCBs, espe-
cially 2-AG, plays a signiﬁcant role in the recovery of the
HPA axis to baseline as an effector in the negative feedback
mechanism initiated by glucocorticoid receptor (GR) activa-
tion in the hippocampus and prefrontal cortex (Wang et al.,
2012). In case of chronic stress, data from animal studies
suggest that prolonged FAAH activity is resulting in chronic
reduction of AEA level which is associated with heightened
anxiety. In line with the above observations, CB1R antagon-
ism enhances the basolateral amygdala excitability andactivates the HPA axis inducing anxiety-like behavior
(Patel et al., 2005; Newsom et al., 2012; Meye et al.,
2013). Consequently, experimental data suggest that
increasing AEA level by FAAH inhibition is an effective
strategy to reduce HPA axis activation and elicit anxiolytic
effect (Haller et al., 2009; Hill et al., 2009), although this
effect was dependent on the investigated brain regions and
conditions of the experiment (Haller et al., 2009).
Because the AEA level is dependent on the enzymatic
activity of the FAAH, the functional genetic variants of the
FAAH gene may play a crucial role in the development of
affective disorders via its regulatory role on the endocanna-
binoid signal. The FAAH C385A polymorphism is a missense
functional variant with a signiﬁcant effect on enzymatic
activity. Results from a study of human T-lymphocytes
suggested that AA genotype carriers have approximately
50% decreased enzymatic activity and also have higher AEA
plasma concentration compared to CC genotype carriers
(Chiang et al., 2004). As it is proposed by some reviews the
FAAH C385A might have signiﬁcant effect on several mental
disorders (Hillard et al., 2012; Gunduz-Cinar et al., 2013a,
2013b), however, only a few human studies addressed this
issue in relation to affective disorders so far.
A signiﬁcant effect of the FAAH C385A has been demon-
strated in the emotional–motivational responses in humans by
two fMRI studies. Hariri et al. reported that A allele of the FAAH
C385A was associated with decreased amygdala reactivity
during a face allocation task involving fearful and angry faces
while an increased ventral striatal reactivity was shown in a
gambling test indicating an association with impulsivity and not
with trait anxiety (Hariri et al., 2009). In another fMRI study, CC
carriers exhibited increased emotional responsiveness towards
unpleasant pictures and reduced emotional reactivity in
response to pleasant pictures (Conzelmann et al., 2012;
Gunduz-Cinar et al., 2013a, 2013b). A allele carriers are better
to habituate to fear and show less stress response (negative
emotionality). Data on FAAH C385A in association with human
anxiety or depression are poorly available. Monteleone et al.
(2010) reported that A allele was presented in a greater number
in patients with bipolar and major depressive disorder than in
healthy controls (Monteleone et al., 2010), although an earlier
study did not ﬁnd any association between the FAAH C385A and
any psychiatric disorders (Sipe et al., 2002).
Despite the central role of the eCB signaling in stress
response, the interacting effect of the FAAH C385A and
stressful life events has not been investigated on affective
disorders so far in human genetic studies.
In this paper we report a signiﬁcant interaction of the
FAAH C385A polymorphism and early childhood trauma on
anxious and depressive phenotypes. This fact draws atten-
tion for a potential pitfall in the recently running clinical
trials of FAAH inhibitors.
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2.1. Study sample
Nine-hundred and twenty-eight unrelated volunteers (30.2%
males and 69.8% females, mean age 31.2710.5) were
recruited in the study from practices of general practitioners,
adult students participating in a long-distance learning pro-
gram and community-based population. The inclusion of sub-
jects was independent of any positive psychiatric anamnesis.
After ﬁltering all missing data, a dataset of 858 subjects were
analyzed in genetic association tests. All subjects were
Hungarian and of Caucasian origin and they have given a
written informed consent before entering the study. The study
was approved by the Central Ethics Committee.
2.2. Phenotypic measurements
2.2.1. Background questionnaire
The Background questionnaire was developed by our team.
It collects some information about the subject's medical
history, educational, employment and marital status. Life-
time prevalence of the depression was measured based on
this instrument. Drug consumption was also questioned in
the instrument. Based on these data nobody used any drugs.
2.2.2. Brief Symptom Inventory
The Brief Symptom Inventory (BSI) is a 26-item self-report
measurement developed from its longer version, the SCL-90-R
(Derogatis, 1993). With the use of the 26-item brief version
questionnaire obsessive–compulsive, interpersonal sensitivity,
depression, anxiety and additional symptoms can be evaluated.
Each item is scored on a 5-point scale ranging from 0 to 4. In this
study we analyzed the anxiety (BSI-ANX) and depression (BSI-DEP)
subscales of the BSI in association with FAAH C385A. We used BSI-
ANX and BSI-DEP as a continuous weighted score similarly to our
previously published papers (Juhasz et al., 2014, 2015).
2.2.3. State-Trait Anxiety Inventory
The State-Trait Anxiety Inventory (STAI) is a 40-item, self-rating
instrument developed for measuring two dimensions of anxiety:
‘trait’ (STAI-T) and ‘state’ (STAI-S) anxiety (Spielberger, 1970).
Both types of anxiety are rated by a 4-point Likert scale scoring
from 1 to 4. State anxiety corresponds to the subject's
emotional condition during the completion of the questionnaire
whereas the trait anxiety is deﬁned as a stable anxious
tendency based on daily experiences of the responders.
2.2.4. Zung Self-Rating Depression Scale
Besides the BSI-DEP subscale, the Zung Self-Rating Depression
Scale (ZSDS) was used to assess the depressive phenotype
(Zung et al., 1965). ZSDS is a 20-item self-rating instrument
(with each item scored on a 4-point Likert scale from 1 to 4)
that measures several types of depression symptoms includ-
ing mood, cognition, impulsivity and suicidal ideation.
The ZSDS is a valid, reliable instrument used in several
studies in order to measure depressive symptoms. Higher
scores correspond to more frequent symptoms, thus this
qualitative scale provided the dependent variable representing
the depressive phenotype in the total sample (Biggs et al.,
1978; Gabrys and Peters, 1985; Agrell and Dehlin, 1989).2.2.5. Childhood Adversity Questionnaire
Childhood adversity (CHA) was evaluated by a shorter version
of the Childhood Trauma Questionnaire (Bernstein et al.,
1997). All four items related to emotional and physical abuse
or neglect are originated from the Childhood Trauma Ques-
tionnaire, and scored on a 5-point Likert scale (from 0 to 4).
The CHA was completed with an additional question con-
cerning the loss of parents during childhood. The sum of
scores was entered into the statistical models in the inter-
action analyses. All statistical analyses included CHA as a
continuous variable. For illustration of the associations
between childhood adversity, FAAH C385A and phenotypic
variant, a categorical variable was created, namely CHA 1 (0
point), CHA 2 (1–3 points) and CHA 3 (more than 3 points).
2.3. Genotyping procedures
Buccal mucosa samples were obtained from all participants
and genomic DNA was isolated according to a protocol
described by Freeman et al. (2003).
A functional polymorphism in upstream of the FAAH gene
(rs324420, also named as C385A) was genotyped using the
Sequenom MassARRAY technology (Sequenom, San Diego).
The IplexTM assay was performed according to the manu-
facturer's instructions (http://www.sequenom.com) using
25 ng of DNA. Genotyping was blinded with regard to
phenotype. All laboratory work was performed under the
ISO 9001:2000 quality management requirements.
2.4. Statistics
Main effects of the FAAH C385A on the phenotypic variables
were analyzed with linear regression analyses using PLINK
v1.07 software (http://pngu.mgh.harvard.edu/purcell/plink/)
under three models (additive, dominant and recessive). To
assess the effect of the childhood adversity in interaction with
the FAAH C385A, linear regression analyses were performed
using the PLINK software and for post hoc tests we applied the
SPSS 20.0 software. To account for multiple testing we applied
the Bonferroni's criteria to correct p-values. Since the associa
tion tests were performed with ﬁve phenotypic instruments
under three genetic models p-values less than 0.0033 were
accepted as signiﬁcant associations (0.05/15=0.0033). All
analyses were adjusted for age and gender.
Minor allele frequencies and Hardy–Weinberg equilibrium
were calculated using the HaploView 4.2 software.
To estimate the power of the analyses we used the
Quanto 1.2 software.
3. Results
3.1. Descriptive statistics
FAAH C385A allele frequencies were 0.79 for C and 0.21 for A.
The genotype distribution (CC=532, CA=287 and AA=42) was
in accordance with the Hardy–Weinberg equilibrium (p=0.382)
and corresponded to available genotype data from other
European populations (HapMap CEU release #28).
Lifetime prevalence of depression and anxiety disorders
reported by the participants were 20.9% and 19.7% in the
1023Genetically reduced FAAH activitystudy sample which is not deviated signiﬁcantly from the
national average (Szadoczky et al., 1998). The proportion of
subjects who scored more than 48 points on the ZSDS was
5.8% which is an estimated prevalence of current episode of
depression and it is also in accordance with the Hungarian
statistics. The mean of Childhood adversity scores was
1.3970.68 and the most frequent answer was zero. Mean
scores and standard deviations on depression and anxiety
scales are shown in Table 1.
Both depressive and anxious phenotypic scores were
higher in women than in men. However, CHA did not
signiﬁcantly differ between the genders.
3.2. Genetic association tests
Main effect of FAAH C385A (rs324420) was not signiﬁcant on
any of the phenotypic variables in any genotypic model
(Table 2). However, carrying A allele meant a two-fold higher
risk to score more than 48 points on ZSDS compared to CC
genotype with a nominal signiﬁcance (OR=2.053, p=0.016).
Interaction analyses with childhood adversity and FAAH
C385A yielded signiﬁcant associations with anxious and
depressive phenotypes under a dominant model. In regres-
sion analyses A allele carriers showed signiﬁcantly higher
BSI-ANX and STAI-T scores than individuals with homozygous
CC genotype of FAAH C385A if they had higher CHA scores
(pinteract=0.00002; pinteract=0.0023, respectively; Table 3).
Depressive phenotypes were also associated with FAAH
C385A and childhood adversity in a similar manner. Sig-
niﬁcantly higher BSI-DEP and ZSDS scores were observed
in FAAH C385A A carriers when they reported chi-
ldhood adversities compared to CC carrier population
(pinteract=0.0005; pinteract=0.004, respectively; Table 3).
In case of STAI-S and ZSDS scales the associations did not
remain signiﬁcant after correction for multiple testing.
Figure 1 shows the mean scores of phenotypic scales in
different genotypes and CHA subgroups (Figure 1).
The estimated power to detect interaction on BSI-DEP
was 93.3% (βG=0.068, βE=0.053, βGE=0.054) and on BSI-
ANX was 98.1% (βG=0.176, βE=0.0367, βGE=0.069).
4. Discussion
This is the ﬁrst report on a signiﬁcant interaction effect of FAAH
C385A polymorphism with childhood adversity on anxiety orTable 1 Mean scores on the depression and anxiety
scales in the total sample.
Measurement Mean7S.D.
BSI-ANX 0.6970.70
BSI-DEP 0.5570.68
STAI-S 37.62711.26
STAI-T 39.66710.59
ZSDS 38.6075.69
BSI-ANX, Anxious subscale of the Brief Symptom Inventory;
BSI-DEP, Depressive subscale of the Brief Symptom Inventory;
STAI-S, State anxiety subscale of the State-Trait Anxiety
Inventory; STAI-T, Trait subscale of the State-Trait Anxiety
Inventory; ZSDS, Zung Self-Rating Depression Scale.depressive phenotypes. We found that those A allele carriers
who experienced high childhood adversity scored higher on BSI-
ANX, STAI-T, BSI-DEP and ZSDS scales compared to CC genotype
carriers with a massive signiﬁcance. In addition, our results on
higher frequency of A allele among subjects with more than 48
points on the ZSDS compared to others are consistent with
ﬁndings of Monteleone et al. (2010). They reported that A allele
of FAAH C385A was presented with a higher number in patients
with bipolar and major depressive disorder (MDD) than in
healthy control population (Monteleone et al., 2010). Never-
theless, signiﬁcance of this association failed to hold after
correction for multiple testing both in our study and in the
study of Monteleone et al. (2010) suggesting that this result
needs to be replicated and clariﬁed in further studies. Inter-
esting to note that the FAAH C385A A allele was the risk variant
for MDD in the Psychiatric Genomics Consortium latest mega-
analysis, although it only showed a trend (p=0.065) (Major
Depressive Disorder Working Group of the Psychiatric GC, 2013).
There are four important aspects to discuss of our results
on the signiﬁcant interaction between childhood adversity
and FAAH C385A on anxiety or depressive phenotypes. First,
the molecular consequence of the genetic variant of FAAH.
Second, the effect of the repetitive stress on the eCB
signaling during neurodevelopment. Third, the role of
gender in the association between eCB and affective
phenotype. The fourth is the potential pharmacogenomic
consequences of these results.4.1. The molecular consequence of the genetic
variant of FAAH
Previous data suggested that A allele of the FAAH C385A is
associated with reduced enzymatic activity and as a con-
sequence with higher AEA level. Several experimental
studies demonstrated that acute inhibition of FAAH through
the increased AEA level was correlated with anxiolytic
effect. However, human data are controversial. Signiﬁcantly
increased AEA level has been found in patients with MDD
(Hill et al., 2008; Ho et al., 2012) and elevated levels of eCB
have been observed in post mortem brain tissues of alco-
holic suicide victims (Vinod et al., 2005).
The anxiolytic effect of AEA is mediated by the CB1Rs
which has inhibitory properties on glutamate release which is
responsible for the activation of HPA axis in stress. As it was
described earlier, this mechanism depends on the amount of
AEA availability and sensitivity and number of CB1R. Perma-
nently elevated AEA level inhibits CB1R expression and lower
density of the CB1Rs are associated with impaired inhibitory
function of the endocannabinoid system resulting in sus-
tained HPA hyperactivity and increased vulnerability to
anxiety. Accordingly, accumulating evidence suggest that
repeated treatment with URB597, a selective FAAH antago-
nist (corresponding similar condition to genetically reduced
enzymatic activity), resulted in a decreased CB1R expression
accompanied by impaired neurogenic cell proliferation and
cell survival in hippocampus and hypothalamus of the rat
brain (Rivera et al., 2015). These data together suggest that
decreased expression of CB1R lead to deﬁnitive changes in
brain structure during neurodevelopment determining later
life behavior. Thus we can assume that in case of A allele
carriers, similarly to chronic FAAH inhibition (Pacher and
Table 2 Main effects of FAAH C385A on the depression and anxiety scales.
n ZSDS n BSI-DEP n BSI-ANX n STAI-S n STAI-T
ADD
CC 529 38.575.5 532 0.5470.67 532 0.6970.7 527 37.1710.9 528 39.5710.3
CA 284 39.375.9 284 0.6570.77 284 0.7370.78 282 38.6711.8 283 41.3711.4
AA 41 37.478.3 42 0.5270.70 42 0.6570.63 41 38.2712.3 41 37.479.9
DOM
CC 529 38.575.5 532 0.5470.67 532 0.6970.69 527 37.1710.9 528 39.5710.3
CA+AA 325 39.076.3 326 0.6370.76 326 0.7270.77 323 38.5711.9 324 40.8711.3
REC
AA 41 37.478.3 42 0.5270.65 42 0.6570.63 41 38.2712.3 41 37.479.9
CA+CC 813 38.875.8 816 0.5870.70 816 0.7070.72 809 37.6711.2 811 40.1710.7
BSI-ANX, Anxious subscale of the Brief Symptom Inventory; BSI-DEP, Depressive subscale of the Brief Symptom Inventory; STAI-S, State
anxiety subscale of the State-Trait Anxiety Inventory; STAI-T, Trait subscale of the State-Trait Anxiety Inventory; ZSDS, Zung Self-
Rating Depression Scale, ADD, additive genetic model; DOM, dominant genetic model; REC, recessive genetic model.
Table 3 Interaction effects of FAAH C385A and childhood adversity on phenotypic variables in linear regression analyses.
Beta S.E. 95% C.I. STAT p
BSI-DEP
FAAH C385A (DOM) 0.07 0.06 0.19–0.06 1.08 ns.
CHA 0.05 0.01 0.03–0.07 5.48 5.64E08
FAAH C385A (DOM)CHA 0.05 0.02 0.02–0.08 3.50 0.0005
BSI-ANX
FAAH C385A (DOM) 0.18 0.07 0.30–0.05 2.71 0.007
CHA 0.04 0.01 0.02–0.06 3.71 0.0002
FAAH C385A (DOM)CHA 0.07 0.02 0.04–0.10 4.32 1.72E05
ZSDS
FAAH C385A (DOM) 0.58 0.53 1.61–0.45 1.10 ns.
CHA 0.37 0.08 0.22–0.53 4.65 3.78E06
FAAH C385A (DOM)CHA 0.37 0.13 0.12–0.62 2.88 0.004
STAI-S
FAAH C385A (DOM) 0.73 1.06 2.81–1.35 0.69 ns.
CHA 0.59 0.16 0.27–0.90 3.64 0.0003
FAAH C385A (DOM)CHA 0.60 0.26 0.09–1.10 2.29 0.0219
STAI-T
FAAH C385A (DOM) 0.97 0.97 2.88–0.93 1.00 ns.
CHA 0.69 0.15 0.40–0.98 4.69 3.11E06
FAAH C385A (DOM)CHA 0.72 0.24 0.26–1.19 3.05 0.0023
BSI-ANX, Anxious subscale of the Brief Symptom Inventory; BSI-DEP, Depressive subscale of the Brief Symptom Inventory; STAI-S, State
anxiety subscale of the State-Trait Anxiety Inventory; STAI-T, Trait subscale of the State-Trait Anxiety Inventory; ZSDS, Zung Self-
Rating Depression Scale; CHA, Childhood Adversity; DOM, dominant genetic model.
J. Lazary et al.1024Kunos, 2013) downregulation of CB1R occur and serves as a
possible mechanism underlying the anxiogenic and depresso-
genic effect of this polymorphism via sustained HPA hyper-
activity and decreased cell proliferation during the
neurodevelopment (Figure 2).
Animal studies repeatedly demonstrated that chronic
stress eventually leads to blunted eCB signaling in the brain
through also downregulation of CB1Rs (Wamsteeker et al.,
2010; McLaughlin et al., 2014; Hill et al., 2005). It has been
proposed that during chronic stress the reduced CB1R density
is due to the inhibitory effect of high corticosteroid level on
CB1R expression. As it has been mentioned above, lower
CB1R density exerts weaker inhibition on glutamate release
which sustains HPA activation. Thus our ﬁndings may reﬂectthe CB1R downregulating effect of the repetitive stress.
However, our ﬁndings underpinned that for phenotypic
manifestation of the affective vulnerability, a combined
effect of the A allele of FAAH C385A with the repetitive
early life stress are needed on CB1R expression (Figure 2).4.2. The effect of repetitive childhood adversity
on eCB signaling during the neurodevelopment
Although the gene encoding the CB1R has been investigated
in interaction with stressful life events (Juhasz et al., 2009;
Agrawal et al., 2012), the FAAH gene together with stress,
especially with childhood traumas were not investigated in
Figure 1 Interactions between FAAH C385A and childhood adversity on anxious and depressive phenotypes.
Figure 2 Different regulatory mechanisms of HPA activations in the hippocampus due to genetic, epigenetic effects in association with
anxiety and depression. Part A: the HPA axis is regulated by a negative feedback mechanism in the hypothalamus involving eCBs as
retrograde messengers. In case of stress response elevated concentration of corticosteroids activates the glucocorticoid receptors (GR)
and they increase the AEA release to the synaptic cleft. The AEA binds to the presynaptically expressed CB1R which mediates an inhibiting
effect on the glutamate release (Wang et al., 2012). With the attenuated level of glutamate the HPA activation declines to the baseline.
Thus, in healthy individuals with a balanced neuroendocrine function, the excitatory effect of the glutamatergic signal is inhibited by
endocannabinoids in association with a low risk for anxiety. Part B: in A allele carriers of FAAH C385A the inhibitory effects of
endocannabinoids on glutamatergic signal is impaired due to a strong reduction of CB1R expression. Reduced activity of the FAAH resulted
in continuously high AEA level causing a downregulation of the CB1R as it was demonstrated by repeated treatment with FAAH inhibitor
(Rivera et al., 2015). Besides, in chronic stress the highly increased corticosteroids block the CB1R expression, too. This double inhibiting
effect on CB1R expression results in a low density of CB1R presynaptically and it leads to a suppressed inhibition on the glutamate release
(Wamsteeker et al., 2010). The higher level of glutamate maintains the activation of the HPA axis with a high risk for anxiety.
1025Genetically reduced FAAH activityassociation with affective phenotypes in human genetic
studies so far. Negative life events in the childhood have
more profound effects on the phenotype than those in the
adulthood since they affect the neurodevelopment of the
brain. Several studies suggest that stressful experiences in
adolescents have prolonged effects to the adulthood yielding
increased anxiety behavior (Avital and Richter-Levin, 2005;Wamsteeker et al., 2010). Thus it is important to note that
the effect of genetic variants in the FAAH gene persists
throughout the neurodevelopment in contrast to a pharma-
cologic inhibition of FAAH in adulthood. Strong evidence
supports that eCB system is involved in the neural develop-
ment, including neurogenesis, glia formation and axonal
elongation. Further, a progressive increase of CB1 receptor
J. Lazary et al.1026concentration was demonstrated in numerous brain areas
between fetal period and adulthood and it was particularly
higher in the limbic area suggesting a signiﬁcant role of CB1R
in the emotional regulation (Fride, 2008). That is why a
genetically reduced FAAH activity can have an altering effect
on the development of neuronal circuits responsible for
stress response. However, genetic variant of FAAH alone does
not yield affective disturbances in our study. It may suggest
that A allele carriers with altered FAAH enzymatic activity
dispose a vulnerable HPA regulation associating with less
psychological resilience and in case of repetitive trauma,
only a maladaptive responsiveness can be produced. Since we
investigated the effect of childhood trauma on anxiety and
depression related phenotypes in adults it can be assumed
that these stressful factors in the early age together with the
FAAH A385 may cause irreversible transformation in the
stress response by exerting molecular and neuroplastic
changes that affect these phenotypes lifelong (Fride, 2008).
4.3. The role of gender in the association
between eCBs and affective phenotypes
There are some data showing that endocannabinoid genes
are differently expressed in males and females in multiple
brain areas, although these data are not consistent in details.
In animal studies lower CB1 receptor expression and
increased CB1 receptor function have been reported in the
hippocampus and the prefrontal cortex of females compared
to males (Mateos et al., 2011; Llorente-Berzal et al., 2013).
Further, in an animal study Marco et al. found that early life
stress was associated with increased endocannabinoid-
related gene expression in the hippocampus in females
whereas in males higher expression of the eCB genes were
found in the frontal cortex (Marco et al., 2014).
However, our results did not show any difference
between men and women. Despite the fact that females
were overrepresented in our sample, it seems that our
signiﬁcant results are not due to genders. We analyzed the
association of FAAH C385A and CHA on the affective
phenotypes separately in men and women and the interac-
tions were nominally signiﬁcant on all phenotypic measure-
ments in both gender subgroups except on ZSDS. This
suggests that the presented G E interaction may be
independent from the gonadal regulation. On the other
hand, behind this genotype–phenotype association a geneti-
cally reduced enzymatic activity is assumed which affects
all brain areas during the neurodevelopment.
4.4. Potential pharmacogenomic consequences
As the selective FAAH inhibitors are considered as potential
anxiolytics and they are under pharmacological development
(www.clinicaltrials.gov/ct2/show/NCT01665573), our results
suggest that evaluating the treatment outcome in human
trials may require the complex analysis of genetic risk factors
and environmental adversities, even in lights of the recently
announced fatal outcome in a clinical trial of FAAH inhibitors
(http://www.nature.com/news/scientists-in-the-dark-after-
french-clinical-trial-proves-fatal-1.19189). Although prompt
effect of FAAH inhibitors can be anxiolytic, experimental data
on repeated treatment of FAAH inhibitor and chronic stresstogether with our results suggest that individuals with differ
ent genetic variants of the FAAH gene and with or without
early life trauma may exhibit divergent reaction (or even
resistance) to an extrinsic FAAH inhibitor because of molecular
alterations in the stress response neurocircuits during neuro
development. Thus, as we previously proposed, pharmacoge
nomic testing of relevant biological pathways and measures of
stressors in different time windows of life are useful and in
some cases necessary tools to predict antidepressant/anxioly
tic or depressogenic/anxiogenic effect of an agent (Lazary
et al., 2009, 2011; Kirilly et al., 2012, 2013).
In conclusion our data revealed a signiﬁcant interaction
between FAAH C385A polymorphism and childhood trauma on
affective phenotypes. In contrast with the acute FAAH
inhibition during acute stress, our results conﬁrmed that
genetically reduced FAAH activity together with chronic early
life stress are anxiogenic. This difference can be explained by
a reduced CB1R receptor expression during neurodevelop-
ment in the human brain, but further studies are needed to
support this hypothesis. Besides, better understanding of the
pathological role of distinctive stressors in the relationship
between eCB system and affective vulnerability may have
great impact on clinical guidelines related to the recently
developing FAAH inhibitors as promising anxiolytic agents.
Limitations
Smoking habits which can be a confounding factor in the
genetic associations on FAAH, CHA and affective phenotypes
were not investigated in our study.
Our sample was not balanced regarding gender ratios;
females were overrepresented in our sample. However,
statistical analyses were adjusted for gender and we
replicated the interaction analyses in both genders.
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